Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · Real-Time Price · USD
231.58
+3.22 (1.41%)
May 5, 2026, 10:02 AM EDT - Market open
Ligand Pharmaceuticals Employees
Ligand Pharmaceuticals had 47 employees as of December 31, 2025. The number of employees decreased by 21 or -30.88% compared to the previous year.
Employees
47
Change (1Y)
-21
Growth (1Y)
-30.88%
Revenue / Employee
$5,703,979
Profits / Employee
$2,647,936
Market Cap
4.64B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 47 | -21 | -30.88% |
| Dec 31, 2024 | 68 | 10 | 17.24% |
| Dec 31, 2023 | 58 | -18 | -23.68% |
| Dec 31, 2022 | 76 | -78 | -50.65% |
| Dec 31, 2021 | 154 | -1 | -0.65% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,965 |
| Caris Life Sciences | 1,846 |
| PTC Therapeutics | 991 |
| Apellis Pharmaceuticals | 739 |
| Crinetics Pharmaceuticals | 594 |
| Travere Therapeutics | 497 |
| TG Therapeutics | 399 |
| CRISPR Therapeutics AG | 393 |
LGND News
- 7 days ago - ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation - PRNewsWire
- 7 days ago - Ligand Bets On Royalty Growth With XOMA Buyout Worth Over $700 Million - Benzinga
- 8 days ago - Ligand Pharma to buy fellow biotech royalty rights buyer XOMA for $739 million - Reuters
- 8 days ago - Ligand Pharmaceuticals Transcript: M&A announcement - Transcripts
- 8 days ago - Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty Aggregator - GlobeNewsWire
- 8 days ago - Ligand Pharmaceuticals Is Buying Xoma for Nearly $740 Million - WSJ
- 13 days ago - Coave Therapeutics to present two posters at ARVO 2026, on first-in-class ligand-conjugated suprachoroidal vector and lead gene therapy program - GlobeNewsWire
- 13 days ago - Ligand to Report First Quarter 2026 Financial Results on May 7, 2026 - GlobeNewsWire